West Pharmaceutical director granted phantom stock units
HAUGEN JANET BRUTSCHEA reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
HAUGEN JANET BRUTSCHEA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services Inc. director Janet Brutschea Haugen reported routine equity-based compensation. She received a grant of 46 Phantom Stock Units tied to common stock, increasing her phantom unit balance to 306.678 units. She also holds 2,113.010 shares of common stock directly, plus 791 restricted stock units and dividend equivalents that will vest in full on the date of the next annual shareholder meeting under the Deferred Compensation Plan for Outside Directors. Awards of phantom stock units are to be settled in shares of stock upon her termination as a director.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 46 shares
Grant/Award
2 txns
Insider
HAUGEN JANET BRUTSCHEA
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Phantom Stock Unit | 46 | $359.00 | $17K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Phantom Stock Unit — 306.678 contracts (Direct);
Common Stock — 2,113.01 shares (Direct)
Footnotes (2)
- F1. Reflects 791 shares of restricted stock units and dividend equivalents that will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.
- F2. Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director.
Key Figures
Phantom stock units granted: 46.0000 units
Price per phantom unit: $359.0000 per unit
Total phantom units after grant: 306.6780 units
+2 more
5 metrics
Phantom stock units granted
46.0000 units
Grant on 2026-06-30 to director as equity award
Price per phantom unit
$359.0000 per unit
Reported transaction price per Phantom Stock Unit
Total phantom units after grant
306.6780 units
Phantom Stock Units held following 2026-06-30 grant
Common stock held
2,113.0100 shares
Direct common stock ownership following reported transactions
Restricted stock units and dividend equivalents
791 units
RSUs vesting at next annual shareholder meeting
Key Terms
Phantom Stock Unit, restricted stock units, dividend equivalents, Deferred Compensation Plan for Outside Directors
4 terms
Phantom Stock Unit financial
"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."
restricted stock units financial
"Reflects 791 shares of restricted stock units and dividend equivalents that will vest in full on the date of the next annual shareholder meeting"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
dividend equivalents financial
"Reflects 791 shares of restricted stock units and dividend equivalents that will vest in full on the date of the next annual shareholder meeting"
Payments tied to employee or contractor equity awards that mirror the cash dividends paid on the company’s stock; they give the holder the same economic benefit as owning the shares without transferring actual shares—often paid in cash or additional award units when the award becomes payable. Investors care because these payments affect a company’s compensation costs, cash flow and potential share dilution, and they signal how management is being rewarded and aligned with shareholders.
Deferred Compensation Plan for Outside Directors financial
"will be distributable under the terms of the Deferred Compensation Plan for Outside Directors."
FAQ
What insider transaction did West Pharmaceutical (WST) report for Janet Brutschea Haugen?
West Pharmaceutical reported that director Janet Brutschea Haugen received a grant of 46 Phantom Stock Units tied to common stock. This is a routine equity-based compensation award rather than an open-market stock purchase or sale.
How many West Pharmaceutical (WST) phantom stock units does the director hold after this Form 4?
After the grant, Janet Brutschea Haugen holds 306.678 Phantom Stock Units. These units are designed to be settled in shares of West Pharmaceutical common stock when she terminates service as a director, aligning her interests with shareholders.
What common stock holdings does Janet Brutschea Haugen report in West Pharmaceutical (WST)?
The Form 4 shows that Janet Brutschea Haugen directly holds 2,113.010 shares of West Pharmaceutical common stock. This figure reflects her direct ownership position following the reported transactions in the filing on the stated date.
What are the terms of the restricted stock units disclosed for West Pharmaceutical (WST)?
The filing notes 791 restricted stock units and dividend equivalents for Janet Brutschea Haugen. These will vest in full on the date of the next annual shareholder meeting and are distributable under the Deferred Compensation Plan for Outside Directors.
How and when will West Pharmaceutical (WST) phantom stock units be settled for the director?
According to the disclosure, phantom stock unit awards are settled in shares of stock upon Janet Brutschea Haugen’s termination as a director. This defers delivery of shares while keeping her compensation tied directly to the company’s equity.
Does this West Pharmaceutical (WST) Form 4 show any insider stock sales or purchases?
The Form 4 reflects a grant of 46 Phantom Stock Units and existing holdings, but no open-market stock purchases or sales. The reported activity is compensation-related, not a discretionary trading transaction in the company’s common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
